Details
Stereochemistry | RACEMIC |
Molecular Formula | C27H21ClN2O2 |
Molecular Weight | 440.921 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=CC=C(Cl)C=C2C(=NC(CC3=CC=C4C=CC=CC4=C3)C1=O)C5=CC=C(O)C=C5
InChI
InChIKey=HIJCSNHREFFOML-UHFFFAOYSA-N
InChI=1S/C27H21ClN2O2/c1-30-25-13-10-21(28)16-23(25)26(19-8-11-22(31)12-9-19)29-24(27(30)32)15-17-6-7-18-4-2-3-5-20(18)14-17/h2-14,16,24,31H,15H2,1H3
Molecular Formula | C27H21ClN2O2 |
Molecular Weight | 440.921 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19768783
https://www.ncbi.nlm.nih.gov/pubmed/17163759
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19768783
https://www.ncbi.nlm.nih.gov/pubmed/17163759
Bz-423 is an inhibitor of the mitochondrial F(1)F(0)-ATPase, with therapeutic properties in murine models of immune diseases.Bz-423,a proapoptotic 1,4-benzodiazepine, potently suppresses disease in the murine model of lupus by selectively killing pathogenic lymphocytes. In MRL/MpJ-Fas(lpr) (MRL-lpr) mice, Bz-423 overcomes deficient expression of the Fas death receptor and hyperactivation of antiapoptotic phosphatidylinositol 3-kinase (PI3K)-Akt signaling to specifically kill pathogenic CD4(+) T cells. Bz-423 binds to the oligomycin-sensitivity-conferring protein component of the mitochondrial F(0)F(1)-ATPase, which modulates the enzyme leading to formation of superoxide by the mitochondrial respiratory chain. Scavenging this reactive oxygen species blocks all subsequent components of the apoptotic cascade. Bz-423 is a promising new drug for treatment of autoimmune diseases, it binds to subunit OSCP of the
mitochondrial enzyme FoF1-ATP synthase and modulates its catalytic activities.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12632430
Mice: treatment mice received Bz-423 (60
mg/kg) injected intraperitoneally.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19706792
Bz-423 (10 uM) activates Bax and Bak in Jurkat cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:31:01 GMT 2023
by
admin
on
Sat Dec 16 08:31:01 GMT 2023
|
Record UNII |
M4Z88L5FCM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
644335
Created by
admin on Sat Dec 16 08:31:01 GMT 2023 , Edited by admin on Sat Dec 16 08:31:01 GMT 2023
|
PRIMARY | |||
|
M4Z88L5FCM
Created by
admin on Sat Dec 16 08:31:01 GMT 2023 , Edited by admin on Sat Dec 16 08:31:01 GMT 2023
|
PRIMARY | |||
|
498576-83-3
Created by
admin on Sat Dec 16 08:31:01 GMT 2023 , Edited by admin on Sat Dec 16 08:31:01 GMT 2023
|
SUPERSEDED | |||
|
216691-95-1
Created by
admin on Sat Dec 16 08:31:01 GMT 2023 , Edited by admin on Sat Dec 16 08:31:01 GMT 2023
|
PRIMARY | |||
|
DTXSID20944275
Created by
admin on Sat Dec 16 08:31:01 GMT 2023 , Edited by admin on Sat Dec 16 08:31:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |